Evotaz NDC 0003-3641

NDC codes

FDA NDC Directory

Product NDC (as listed)0003-3641Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00003-3641Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0003-3641-11	00003364111	30 TABLET in 1 BOTTLE (0003-3641-11)Marketed from Jan 29, 2015

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Evotaz
Generic name (nonproprietary): atazanavir and cobicistat
Active ingredients: Atazanavir sulfate — 300 mg/1Cobicistat — 150 mg/1
Dosage form: Tablet
Route: Oral
Labeler: E.R. Squibb & Sons, L.L.C.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 206353
Marketing start: Jan 29, 2015
Listing expires: Dec 31, 2026
Other FDA classes: Breast Cancer Resistance Protein Inhibitors (Mechanism)Cytochrome P450 2C8 Inhibitors (Mechanism)Cytochrome P450 2D6 Inhibitors (Mechanism)Cytochrome P450 3A Inhibitors (Mechanism)Cytochrome P450 3A Inhibitors (Mechanism)Cytochrome P450 3A4 Inhibitors (Mechanism)HIV Protease Inhibitors (Mechanism)Multidrug and Toxin Extrusion Transporter 1 Inhibitors (Mechanism)Organic Anion Transporting Polypeptide 1B1 Inhibitors (Mechanism)Organic Anion Transporting Polypeptide 1B3 Inhibitors (Mechanism)P-Glycoprotein Inhibitors (Mechanism)UDP Glucuronosyltransferases Inhibitors (Mechanism)UGT1A1 Inhibitors (Mechanism)
Identifiers: Product ID 0003-3641_fa642c67-5a9e-4136-a141-64e1236f6a0fSPL ID fa642c67-5a9e-4136-a141-64e1236f6a0fSPL set ID 83db29d7-5d85-49d6-8cb6-740473365cf8RxCUI 1601654, 1601660UNII 4MT4VIE29P, LW2E03M5PG
Pharmacologic class: Cytochrome P450 3A Inhibitor; Protease Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400003364111 followed by a unit qualifier and the quantity

Package 00003-3641-11. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 12, 2025.

Indications (excerpt from the label)

EVOTAZ is a two-drug combination of atazanavir, a human immunodeficiency virus (HIV-1) protease inhibitor, and cobicistat, a CYP3A inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV‑1 infection in adults and pediatric patients weighing at least 35 kg. (1) Limitations of Use Use of EVOTAZ in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions. (1) 1.1 Indications EVOTAZ ® is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in the following populations [see Dosage and Administration (2.2 , 2.3) ]…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)